Natura Considers Avon Separation; LVMH Highlights Sephora Growth In 2023; Beauty News In Brief

Splitting off Avon as its own publicly traded company would unlock shareholder value and provide shareholders with greater visibility into the entities’ performance and potential, Natura says. Sephora sales fueled 20% reported growth in LVMH’s Selective Retailing business in 2023. More beauty news.

Beauty News
• Source: Shutterstock

Brazilian beauty giant Natura & Co reports its board of directors has authorized management to assess a possible separation of Natura & Co Latin America and its Avon division to “unlock further shareholder value.” Noting the two entities’ distinct geographical footprints and service to different beauty consultants and consumers, the Sao Paulo-based firm said on 5 February the move would result in two independent, publicly traded beauty companies – Natura and Avon – with “unique business plans, independent governance and management teams, better equipped to pursue more tailored strategies to drive long-term shareholder value.” A separation also would “afford shareholders greater visibility into the financial performance, structure, growth prospects and investment theses of the respective companies,” Natura & Co. says. Natura & Co. acquired Avon in early 2020. (Also see "Natura Making Strong Headway In The Body Shop Transformation; Next Up, Avon" - HBW Insight, 28 August, 2019.)

Under the plan, Natura would operate the Natura brand worldwide as well as the Avon brand in Latin America, while...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Deals

Nancy Tests Arc AI Editor

 
• By 

Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

L’Oreal Acquires 10% Stake, Plans R&D Collaboration With Galderma

 

L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.